APA
Nguyen H. T., Nguyen N., Liu L. Y., Dovek L., Lenchner D., Harris R., Ozer B., Ravelo A., Sommer N., Sim M. S., Elashoff R., Green R., Nghiemphu P. L., Cloughesy T. F., Ellingson B. & Lai A. (2019). Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. : Neuro-oncology practice.
Chicago
Nguyen Huy Tram, Nguyen Nhung, Liu Liang Yen, Dovek Laura, Lenchner Daniel, Harris Robert, Ozer Byram, Ravelo Arliene, Sommer Nicolas, Sim Myung Shin, Elashoff Robert, Green Richard, Nghiemphu Phioanh Leia, Cloughesy Timothy Francis, Ellingson Benjamin and Lai Albert. 2019. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. : Neuro-oncology practice.
Harvard
Nguyen H. T., Nguyen N., Liu L. Y., Dovek L., Lenchner D., Harris R., Ozer B., Ravelo A., Sommer N., Sim M. S., Elashoff R., Green R., Nghiemphu P. L., Cloughesy T. F., Ellingson B. and Lai A. (2019). Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. : Neuro-oncology practice.
MLA
Nguyen Huy Tram, Nguyen Nhung, Liu Liang Yen, Dovek Laura, Lenchner Daniel, Harris Robert, Ozer Byram, Ravelo Arliene, Sommer Nicolas, Sim Myung Shin, Elashoff Robert, Green Richard, Nghiemphu Phioanh Leia, Cloughesy Timothy Francis, Ellingson Benjamin and Lai Albert. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. : Neuro-oncology practice. 2019.